United Therap patent expiration

1. Orenitram patent expiration

ORENITRAM's oppositions filed in EPO
ORENITRAM IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6765117 UNITED THERAP Process for stereoselective synthesis of prostacyclin derivatives
Oct, 2017

(6 years ago)

US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month ago)

US7417070 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2026

(2 years from now)

US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5153222 UNITED THERAP Method of treating pulmonary hypertension with benzidine prostaglandins
Oct, 2014

(9 years ago)

US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month ago)

US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month ago)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month ago)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2024

(4 days ago)

US9393203 UNITED THERAP Osmotic drug delivery system
Apr, 2026

(1 year, 9 months from now)

US8410169 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Feb, 2030

(5 years from now)

US8349892 UNITED THERAP Solid formulations of prostacyclin analogs
Jan, 2031

(6 years from now)

US8747897 UNITED THERAP Osmotic drug delivery system
Aug, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 20, 2016
New Dosing Schedule(D-156) Jan 28, 2019
New Dosing Schedule(D-157) Jan 28, 2019
Orphan Drug Exclusivity(ODE-308) Dec 20, 2020
New Indication(I-820) Oct 18, 2022
Orphan Drug Exclusivity(ODE-272) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically accept...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage

ORENITRAM family patents

Family Patents

2. Remodulin patent expiration

REMODULIN's oppositions filed in EPO
REMODULIN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5153222 UNITED THERAP Method of treating pulmonary hypertension with benzidine prostaglandins
Oct, 2014

(9 years ago)

US6765117 UNITED THERAP Process for stereoselective synthesis of prostacyclin derivatives
Oct, 2017

(6 years ago)

US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(a month ago)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil
Dec, 2024

(4 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil
Dec, 2024

(4 months from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil
Dec, 2024

(4 months from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(4 years from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(4 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Mar, 2029

(4 years from now)




Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 28 September, 2023

Treatment: Treatment of pulmonary hypertension with ut-15; Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration...

Dosage: INJECTABLE; SOLUTION

How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage

REMODULIN family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Tyvaso patent expiration

TYVASO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5153222 UNITED THERAP Method of treating pulmonary hypertension with benzidine prostaglandins
Oct, 2014

(9 years ago)

US6765117 UNITED THERAP Process for stereoselective synthesis of prostacyclin derivatives
Oct, 2017

(6 years ago)

US6756033 UNITED THERAP Method for delivering benzindene prostaglandins by inhalation
Nov, 2018

(5 years ago)

US6521212 UNITED THERAP Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
Nov, 2018

(5 years ago)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(2 years from now)

US10376525 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(2 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(3 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(3 years from now)

US11826327 UNITED THERAP Treatment for interstitial lung disease
Feb, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jul 30, 2012
Orphan Drug Exclusivity(ODE) Jul 30, 2016
M(M-145) May 20, 2017
New Indication(I-856) Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Treatment of pulmonary hypertension; Treatment of pulmonary hypertension by inhalation; Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a ...

Dosage: SOLUTION

How can I launch a generic of TYVASO before it's drug patent expiration?
More Information on Dosage

TYVASO family patents

Family Patents

4. Tyvaso Dpi patent expiration

TYVASO DPI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(4 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

US11723887 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(1 year, 1 month from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(2 years from now)

US10772883 UNITED THERAP Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(5 years from now)

US10421729 UNITED THERAP Microcrystalline diketopiperazine compositions and methods
Apr, 2035

(10 years from now)

US11826327 UNITED THERAP Treatment for interstitial lung disease
Feb, 2042

(17 years from now)




Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device; Method of treating pulmonary hypertension associated with interstitial lung dise...

Dosage: POWDER

More Information on Dosage

TYVASO DPI family patents

Family Patents